Tags : Exercises

BMS Exercises its Option to Globally License Obsidian’s CD40L Cell

Shots: BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian’s cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L In 2019, the companies collaborated to develop novel cell therapies, under which Obsidian is eligible to receive milestones and royalties on sales of therapies. Exercising the […]Read More

AbbVie Exercises its Option to License Morphosys’ αvβ6 Integrin Inhibitor

Shots: Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option under the companies’ R&D collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for fibrotic diseases including IPF and additional indications The license covers αvβ6 integrin […]Read More

Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478

Shots: Idorsia to receive $45M upfront in cash, $365M for development & regulatory milestone, one-time sales threshold and royalties on sales. Additionally, will receive $7M in funding to discover, identify and develop additional novel T-type calcium channel blockers Neurocrine exercises its option to license rights for ACT-709478 (post IND acceptance from the US FDA on […]Read More

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for

Shots: Takeda acquires PvP Biologics following the P-I proof-of-mechanism study of TAK-062 (Kuma062) to treat uncontrolled celiac disease. Takeda exercises its option to acquire by paying ~$330M as development & regulatory milestone including $35M up front In 2017, the companies collaborated to develop novel therapies for celiac disease, under which Takeda got exclusive option to […]Read More

Immunic Exercises its Worldwide Exclusive Option to License for IMU-856

Shots: Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries, including the US, EU, and Japan Additionally, the option includes patent […]Read More

Alexion Exercises its Option to License Dicerna’s Two Additional GalXC

Shots: Alexion to pay $20M as an option exercise fee in exchange for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC RNAi molecules In Oct’2018, the companies collaborated to develop GalXC RNAi (SC) targeting four complement pathway therapies for the treatment of complement-mediated diseases. Under the […]Read More

GSK Exercises Its Option to License Ionis’ Antisense Therapy for

Shots: Ionis to receive ~$262M milestones including $25M license fee with royalties on sales of products. GSK to exercise its option to license program following positive P-II results and will be responsible for all development, regulatory, commercialization activities and its costs  In Mar’2010, GSK and Ionis collaborated on RNA therapies for rare and infectious diseases […]Read More

Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for

Shots: Sarepta exercises its option to acquire Myonexus Therapeutics, in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C In May,2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD, paying $60M upfront & milestones, gaining excsluive […]Read More

Novartis Exercises its Option to License AKCEA-APO(a)-LRx from Akcea

Shots: Akcea to receive $150M as option license fee with equal sharing with Ionis as equity investment in Akcea. Novartis to get exclusive WW development and commercialization rights for Akcea’s AKCEA-APO(a)-LRx (TQJ230) and will initiate P-III trial for cardiovascular outcomes In Jan,2107 Akcea and its subsidiary Ionis collaborated with Novartis to develop & commercialize AKCEA-APO(a)-LRx […]Read More